Advances in CRISPR technologies promise to accelerate the burgeoning pipeline of gene-editing therapies and broaden access to these disease-altering therapies.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...

Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy ...

MaxCyte Inc. (NASDAQ: MXCT) is a global developer of next-generation cell therapies. They provide crucial technology for cell ...

BizTimes Media’s 24th annual Economic Trends event on Thursday featured insights and predictions from an economist, local business leaders and an academic ...

its CRISPR medicine for sickle cell and beta thalassemia. We recently compiled a list of the Top 11 CRISPR Stocks to Invest In. In this article, we are going to take a look at where CRISPR ...

Vertex and CRISPR Therapeutics have won the backing ... a few months after turning it down for sickle cell disease. Final draft guidance published this morning clears Casgevy (exagamglogene ...

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox.

Beam Therapeutics shows promise in gene therapy for sickle cell disease, but it also has high risks and market expectations.

A gene-editing drug developed by CRISPR Therapeutics and Vertex Pharma has achieved “remarkable” improvements in patients with beta thalassaemia and sickle cell disease in an early-stage trial ...

Read about the top 15 political, economic, social, environmental, technology and industry trends that will shape 2025 and beyond ...